Gender neutral vaccination against HPV
BMJ 2018; 362 doi: https://doi.org/10.1136/bmj.k3837 (Published 17 September 2018) Cite this as: BMJ 2018;362:k3837- Ned Powell, HPV Research Group lead1,
- Sam Hibbitts, dean of equality, diversity, and inclusivity1,
- Mererid Evans, consultant oncologist2
- 1School of Medicine, Cardiff University, UK
- 2Velindre Cancer Centre, Cardiff, UK
- powellng@cardiff.ac.uk
Human papillomavirus (HPV) is a common sexually transmitted virus and the cause of nearly all cervical cancers. In 2008, the UK governments implemented a school based HPV vaccination programme for 12-13 year old girls. This has already substantially decreased HPV prevalence in target populations.1 When HPV vaccination was introduced, the focus was understandably on preventing cervical cancer. This facilitated a very clear and effective public health message, and in recent years vaccine uptake in the UK has remained consistently high (over 80%).2
Over the past decade, however, awareness of the burden of HPV attributable cancers in men has increased. Oropharyngeal cancers, primarily cancers of the tonsils and tongue base, have become more common across the developed world. In the UK, between 2002 and 2011, incidence of oropharyngeal cancers increased by 101%, with three quarters of cases occurring in men, and more than half being caused by HPV.3 In England in 2016, there were 8.9 oropharyngeal cancers per 100 000 men, compared with …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.